Midostaurin - Novartis Oncology
At a glance
- Drug Originator Novartis
- Drug Class Antineoplastics; Carbazoles; Eye disorder therapies; Indole alkaloids; Skin disorder therapies; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein kinase C inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-2 antagonists
- USA Patent Applicants NOVARTIS
- USA Patents 5
- NDAs 1
- International Patents 62
- Patent Applications 3,851
Table of Contents

Disclaimer